AbD Serotec Secures Exclusive Worldwide Manufacturing License to Key Research Antibodies from VU University
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
MorphoSys AG announced that its research and diagnostic antibodies unit AbD Serotec has signed a license agreement with VU University Medical Center (VUmc), which provides AbD Serotec with worldwide exclusive rights to commercialize a number of antibody clones for research applications. These include the world's most widely used reagents for studying macrophage subsets in rats, the "ED series" of antibodies.
The antibodies are key reagents for studying various cell types and processes which play a central role in the innate immune system. The innate immune system forms an initial line of defense against diverse invading foreign pathogens and damaged or infected host cells. It acts through a variety of primitive and more advanced mechanisms, including the complement cascade, pattern recognition receptors, and macrophages to identify and target foreign intruders.
In addition, it initiates the host's adaptive immune response via antigen presentation by dendritic cells. The original paper on the ED antibodies is a key publication in the field being cited over 1,600 times.
"In line with our strategy to achieve a market-leading position in key focus areas, we have decided to further expand our offering in innate immunity research and take an exclusive manufacturing license for a range of ED antibody clones from the VU University Medical Center," commented Dieter Feger, Head of AbD Serotec. "AbD Serotec already provides an extensive collection of antibodies for studying the activities and actions of the innate immune system, all manufactured to highest quality standards and guaranteed for use in important applications such as flow cytometry and western blotting."
The antibodies are key reagents for studying various cell types and processes which play a central role in the innate immune system. The innate immune system forms an initial line of defense against diverse invading foreign pathogens and damaged or infected host cells. It acts through a variety of primitive and more advanced mechanisms, including the complement cascade, pattern recognition receptors, and macrophages to identify and target foreign intruders.
In addition, it initiates the host's adaptive immune response via antigen presentation by dendritic cells. The original paper on the ED antibodies is a key publication in the field being cited over 1,600 times.
"In line with our strategy to achieve a market-leading position in key focus areas, we have decided to further expand our offering in innate immunity research and take an exclusive manufacturing license for a range of ED antibody clones from the VU University Medical Center," commented Dieter Feger, Head of AbD Serotec. "AbD Serotec already provides an extensive collection of antibodies for studying the activities and actions of the innate immune system, all manufactured to highest quality standards and guaranteed for use in important applications such as flow cytometry and western blotting."
